In May 2026, BrightGene Bio-Medicals Phase III clinical trial evaluating its dual-agonist injection, BGM0504, successfully met its primary endpoint and all key secondary endpoints for overweight and obesity management
Colberts Nano-Glutathione Dropper helps support your bodys natural antioxidant defenses and detoxification pathways
Are macros different on tirzepatide than semaglutide
Explore the Lumo+ Pairing Partner Week by Week, Weeks 1 Through 12 Hydration and Glow The first visible change is barrier hydration
The potential nephroprotective effects of GLP-1RAs had been reported in a further analysis of renal outcomes in a series of CVOTs trials that showed reduction in proteinuria and hinted at slowing eGFR decline
Over the past year, this GLP-1 has become a hit among gym-goers, even though its still being vetted in clinical trials overseen by Eli Lilly